Cannell & Spears’s Novo Nordisk NVO Stock Holding History

Cannell & Spears’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$447K	Buy	9,329 +1,377	+17%	+$59.2K	0.01%	325
2026 Q1	$292K	Sell	7,952 -5,570	-41%	-$264K	0.01%	361
2025 Q4	$688K	Buy	13,522 +1,575	+13%	+$80.5K	0.01%	266
2025 Q3	$663K	Sell	11,947 -27,102	-69%	-$1.59M	0.01%	267
2025 Q2	$2.7M	Sell	39,049 -24,776	-39%	-$1.69M	0.05%	176
2025 Q1	$4.43M	Buy	63,825 +27,148	+74%	+$2.24M	0.1%	139
2024 Q4	$3.15M	Buy	36,677 +31,696	+636%	+$3.43M	0.06%	161
2024 Q3	$593K	Buy	4,981 +90	+2%	+$12K	0.01%	284
2024 Q2	$698K	Buy	4,891 +651	+15%	+$86.3K	0.01%	245
2024 Q1	$544K	Buy	4,240 +20	+0.5%	+$2.38K	0.01%	274
2023 Q4	$437K	Buy	4,220 +2,000	+90%	+$198K	0.03%	144
2023 Q3	$202K	Buy	+2,220	New	+$196K	0.02%	200
2021 Q4	–	Sell	-11,300	Closed	-$542K	–	243
2021 Q3	$542K	Buy	+11,300	New	+$546K	0.04%	139

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cannell & Spears's NVO Position: Q2 2026 in Review

Cannell & Spears increased its Novo Nordisk (NVO) stake by 17% in Q2 2026, buying an estimated $59.2K and bringing the position to 9,329 shares worth $447K. The position accounts for 0.01% of the portfolio, ranked #325.

Cannell & Spears first reported a position in NVO in Q3 2021 and has held it in 13 quarters since. The position peaked at $4.43M in Q1 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Cannell & Spears held 9,329 shares of Novo Nordisk worth $447K as of Q2 2026.
Cannell & Spears bought 1,377 Novo Nordisk shares in Q2 2026, an estimated $59.2K.
Novo Nordisk made up 0.01% of Cannell & Spears's portfolio in Q2 2026, its #325 holding.
Cannell & Spears first reported a position in Novo Nordisk in Q3 2021 and has held it in 13 quarters since.
Cannell & Spears's Novo Nordisk position peaked at $4.43M in Q1 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cannell & Spears's 13F filing for Q2 2026, filed 11 Aug 2026.